Barely Significant
← all excerpts

Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia.

Front Immunol · 2022 · PMC9663847 · PMID 36389764

Europe PMCDOI
1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

highly significantp < 0.0001actually significant
Comparison of survival curve using a log-rank (Mantel–Cox) test showed a highly significant difference between mice treated with control ATCs and mice treated with CD33GO BATs (p < 0.0001), control ATCs vs.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.